ArticleAlzheimer's research & therapy2025

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database.

Michael Irizarry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.